|1.||Kapikian, Albert Z: 3 articles (08/2013 - 02/2006)|
|2.||Vesikari, Timo: 3 articles (08/2013 - 02/2006)|
|3.||Hoshino, Yasutaka: 2 articles (08/2006 - 02/2006)|
|4.||Forrest, Bruce D: 2 articles (08/2006 - 02/2006)|
|5.||Chanock, Robert M: 2 articles (08/2006 - 02/2006)|
|6.||González, Rosabel: 2 articles (10/2005 - 08/2005)|
|7.||Bresee, J S: 2 articles (12/2001 - 11/2000)|
|8.||Linhares, A C: 2 articles (11/2000 - 07/2000)|
|9.||Ruiz, Leonard P: 1 article (08/2013)|
|10.||Jacobson, Robert M: 1 article (08/2013)|
07/01/2000 - "RRV-TV was also shown to be 75% protective against very severe gastroenteritis in northern Brazil. "
02/01/1998 - "RRV-TV has similar overall efficacy to RRV-S1, but provides greater protection against gastroenteritis caused by rotavirus strains of serotypes other than G1. "
05/01/1999 - "Stool specimens from 1528 episodes of acute gastroenteritis (805 in the placebo group and 723 in the RRV-TV vaccine group) were tested for astrovirus with a sensitive reverse transcription-polymerase chain reaction (RT-PCR) assay and positive results were confirmed by Southern hybridization using probes specific for astrovirus serotypes 1 and 2. Astroviruses were detected in 144 (9%) episodes of gastroenteritis; 92% of the findings were serotype 1 and 6% were serotype 2. The astrovirus peak season was in winter. "
10/01/1997 - "During the first year of surveillance, the estimates of vaccine efficacy (with 95% confidence interval) for preventing rotaviral gastroenteritis were 50% (26, 67) for RRV-TV and 29% (-1, 50) for RRV-S1. "
08/01/2013 - "This study examined RRV-TV for the prevention of rotavirus gastroenteritis (RV-GE) in Ghana, West Africa, with infants receiving the first dose during the neonatal period and the second before 60 days of age. "
10/23/1997 - "Although a rhesus rotavirus-based quadrivalent vaccine is highly effective in preventing severe diarrhea in developed countries, in developing countries its efficacy has been less impressive. "
11/01/1999 - "These trials should use catchment designs and focus on the evaluation of the efficacy of one or three doses of RRV-TV against moderate to severe/very severe rotavirus diarrhea."
12/01/2001 - "In this population RRV-tetravalent vaccine was comparably immunogenic and safe as in trials conducted in developed countries, where this vaccine has been proved effective in preventing severe rotavirus diarrhea. "
10/01/1998 - "In clinical trials in industrialized countries, RRV-TV conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease. "
02/01/1996 - "Only the RRV vaccine induced a low level of protection against rotavirus diarrhea mainly of serotype G1 specificity. "
10/01/2005 - "Following natural infection or RRV-TV vaccination, NSP4 was significantly less immunogenic than the VP6 protein when these responses were independently measured by ELISA. "
10/01/2005 - "Our findings indicate that NSP4 evokes significantly (P < 0.05) higher seroconversion rates after natural infection than after RRV-TV vaccination. "
08/01/1991 - "In this article, we report the characterization of the intestinal antibody response of a murine model to heterologous infection with the rhesus rotavirus vaccine strain. "
08/01/2001 - "The workshop reviewed the current understanding of the possible association between RRV-TV and intussusception, as well as the possible association between a variety of viral infections and intussusception. "
05/31/2011 - "Also, RRV vaccine-induced antibodies were partially cross-protective against infection with a related alphavirus, Chikungunya virus, and did not enhance infection. "
|1.||rhesus rotavirus vaccine
|4.||RNA-Directed DNA Polymerase (Reverse Transcriptase)
|6.||Hepatitis B Vaccines (Hepatitis B Vaccine)
|8.||Immunoglobulin A (IgA)
|9.||Respiratory Syncytial Virus Vaccines
|10.||Chickenpox Vaccine (Vaccine, Varicella)